Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US OBESITY COMPETITIVE INTELLIGENCE
US OBESITY COMPETITIVE INTELLIGENCE
Tirzepatide delivered 20.9% weight loss versus semaglutide's 15.3%, but Medicare Part D still excludes anti-obesity drugs for 50 million beneficiaries....



